MoonLake Immunotherapeutics (MLTX)

Infravalorada

HealthcareBiotechnologySwitzerland

Fundamental

Precio

$11.70

Capitalización Bursátil

$996M

Yahoo Finance TradingView Noticias Sitio web

Parte 1 · Cuánto vale la empresa

Resumen

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 19 de septiembre de 2026 with claude-haiku-4-5 — shared with all users

AbbVie IncABBV

P/E: 73.9Score: 75Market cap: $470.55B

AbbVie's adalimumab (Humira) was the first biologic approved for hidradenitis suppurativa and still defines first-line treatment, while its risankizumab (Skyrizi) competes in psoriatic arthritis — both were used as active reference arms in MoonLake's own trials.

Eli Lilly and CompanyLLY

P/E: 38.8Score: 78Market cap: $1.11T

Lilly's ixekizumab (Taltz) is an IL-17A inhibitor prescribed for psoriatic arthritis, axial spondyloarthritis and plaque psoriasis, the rheumatology and dermatology indications sonelokimab is being developed for beyond hidradenitis suppurativa.

Incyte CorporationINCY

P/E: 17.1Score: 82Market cap: $24.86B

Incyte is bringing povorcitinib, an oral JAK1 inhibitor, through late-stage trials in hidradenitis suppurativa, competing for the same patients with a pill rather than an injection.

UCB S.A.UCB

UCB's bimekizumab (Bimzelx) blocks the same IL-17A and IL-17F cytokines as sonelokimab and is already approved for hidradenitis suppurativa and psoriatic arthritis, the two indications MoonLake is bringing to market.

Novartis AGNVS

Novartis sells secukinumab (Cosentyx), the IL-17A inhibitor approved in 2023 for hidradenitis suppurativa and widely used in psoriatic arthritis and axial spondyloarthritis, addressing the same dermatology and rheumatology prescribers MoonLake targets.

Fuentes: MoonLake Immunotherapeutics — Form 10-K, fiscal year 2024 MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab New HS Treatments: Latest FDA-Approved Options

Balance y Liquidez

Ingresos

Ejercicio cerrado el 31/12/2025

Beneficio Neto

$-227M

Ejercicio cerrado el 31/12/2025

Flujo de Caja Libre

$-196M

Patrimonio Neto Total

$304M

Pasivo Total

$120M

Ratio de Liquidez

12.56

Cobertura de Intereses

26.58

Deuda/EBITDA

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

No hay datos de ingresos disponibles

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Pre-ingresosInfravalorado

Valor Justo

$28.54

Precio Actual

$11.70

Margen de Seguridad

+59.0%

Rango de Valor Justo

$27.11 - $29.97

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$28.54

Flujo de caja descontado (DCF):No aplicable a este tipo de empresa

Múltiplo sobre beneficios (P/E):No aplicable a este tipo de empresa

Fórmula de crecimiento de Graham:No aplicable a este tipo de empresa

Valor de la capacidad de generar beneficios (EPV):No aplicable a este tipo de empresa

P/B justificado:No aplicable a este tipo de empresa

Descuento de dividendos (Gordon):No aplicable a este tipo de empresa

P/FFO, fondos de operaciones:No aplicable a este tipo de empresa

Beneficios de mitad de ciclo:No aplicable a este tipo de empresa

Múltiplo sobre ingresos:Datos insuficientes para calcularlo

Consenso de Analistas:Comprar (17B / 3H / 2S)

Última Sorpresa de Resultados:+10.35%

Métricas de Valoración

Ratio P/E

ROE

-74.7%

Ratio P/B

2.33

P/FCF

Margen Bruto

ROIC

-40.1%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

-40.1%

WACC

10.3%

ROIC − WACC

-50.4 pp

El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.

Criterios de Análisis Fundamental

Superado (7)

P/B Ratio 2.33
Debt/Equity ratio
Current Ratio
Interest Coverage
Low reliance on intangibles
Analyst Consensus 77% Buy
Share Dilution 2.3%

Fallido (9)

EPS shows upward trend
Price CAGR 2.13%
ROIC -40.1%
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -82.7%
Earnings Surprise avg -2.8%
Piotroski F-Score 1/9

No disponible (11)

Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
Operating Margin NaN%
CapEx intensity
Debt/EBITDA
Price below Graham Number
Revenue Growth 5Y (Finnhub)
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)
Net Margin Trend (invalid data)

Piotroski F-Score

1/9

Preocupaciones financieras graves

score

criteria

Calidad de los Beneficios

Baja calidad: investigue la contabilidad

Dilución de Acciones

2.3%

Emitiendo nuevas acciones, diluyendo la participación

Participaciones institucionales

Gobernanza

Equipo Directivo

Nombre	Cargo	Edad
Dr. Jorge Santos da Silva Ph.D.	Co-Founder, Interim Chair of the Board & CEO	48
Dr. Kristian Reich M.D., Ph.D.	Co-Founder & Chief Scientific Officer	59
Mr. Matthias Bodenstedt	Chief Financial Officer	37
Mr. Oliver Daltrop Ph.D.	Chief Technical Officer	-
Ms. Carla Bretes	Director of Investor Relations & External Communications	-
Mr. Nicolas Mosimann Ph.D.	General Counsel	-
Joana Cortez	Associate Vice-President of Legal & Compliance	-
Tino Anthamatten	Vice President of Marketing, Market Access & Pricing	-
Luciana Marques	Associate Vice-President of HR, People and Culture	-
Ms. Nuala Brennan	Chief Clinical Development Officer	-

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Documentos

Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-25
Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-10
Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-30
Ver documento

via SEC EDGAR

Historial de Resultados

via SEC EDGAR

Latest News

Recent headlines for MLTX, sourced from Markets Gazette.

3/30/2026POSITIVE
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.

via Markets Gazette